Here, we report the results of a single-center study on the prevalence of ACE-2 polymorphisms in a small cohort of SARS-CoV-2-infected patients with various clinical phenotypes of COVID-19, aiming to evaluate the potential utility of these polymorphisms as prognostic markers in routine clinical practice. This evidence concerns the gene ACE2 and COVID-19.